Category : Cancer Treatment Therapies

Cancer Treatments Are Going To Be Changing In The Near Future With Eric Lefkofsky’s Tempus Technology

Eric Lefkofsky earned his degree in 1991 from the University of Michigan, followed by earning his Juris Doctor degree from law school. Along with earning his degrees and building an impressive academic background, Eric Lefkofsky also has the mind of an entrepreneur, as he has started up several successful companies that have contributed to his vast amount of success and his fortune. Most people have heard of his app Groupon, which offers coupons to people so they can save money when they go out to eat and travel. Eric Lefkofsky’s latest efforts in business following his academic background is Tempus. This company will focus on genomic sequencing and amassing data from throughout the medical field to improve research and create precise treatments for cancer patients.

The foundation of Tempus lies in analytics software that will allow the company to compile that vast amounts of loose data around the world in healthcare service and cancer. Eric Lefkofsky says that the disorganization of data in the healthcare industry is massive and leaves treatments, especially related to cancer, to generalized for each patient.

Eric is not only the Co-founder of Tempus, he also works alongside his wife managing the Lefkofsky foundation. On top of this, Eric manages other businesses and is a member for several other organizations as a member of the board. In his spare time, he also gives speeches to teach students about business and tech as well as being an entrepreneur.

When it comes to the world of technology, things are always advancing. The same thing can be said of the healthcare industry. Despite that, however, there is a challenge in the healthcare industry for providing patients with proper and specialized care that has been accurately created to fit each patient’s needs. Eric Lefkofsky is creating a solution for that problem through Tempus alongside Co-founder Brad Keywell. As Tempus continues to compile data from the field of healthcare around the world, the healthcare practice as a whole will be aided with more specific and accurate data for treatments.

About Eric Lefkofsky:

Clay Siegall Is A Pioneer In The Field Of Cancer Treatment Therapies.


Analytical cancer therapy exploratory institution Seattle Genetics is exceedingly well-liked at present. The President and Chief Executive Officer of the institution is Clay Siegall. He’s also the highly respected co-founder of the institution, which was formed in 1998. Clay Siegall is also positioned as their chairman on the committee’s board. Ever since the formation of his esteemed career as an advanced biomedical examiner, Clay has demonstrated an impressive history of taking the appropriate steps to accomplish what is mandatory to lend a hand to patients who put up with cancer. Dr. Siegall’s peers declare that they think of him as a conscientious and faithful doctor. Clay steered the institution towards making strong advances on helping cancer sufferers, and the utilization of highly advanced approaches to helping cancer patients.

His steadfast dedication to examining cancer treatment alternatives is highly documented. Dr. Siegall utilizes only the most high-tech, highly advanced methods, which are mandatory in the forming of what is known as antibody-drug conjugates. This progress helped Seattle Genetics win an approval from the highly respected FDA in 2011. As Seattle Genetics stretched out their institution’s profile, they rapidly became proficient at supporting a wide range of cancer survivors all over the world.

Dr. Siegall was awarded with the honorable Alumnus of the Year, from the College of Maryland, in 2013, for high great achievements in Math and also in Natural Sciences. Seattle Genetics is proud to be the recipient of a staggering $1.2 billion gift, made possible by the hard work of Dr. Siegall. Many people, believe that this additional revenue was responsible for the institution of truly advanced methods that help to provide comfort to survivors of cancer, using radical technology.

Clay gained the status of the Foremost Scientist, presented by the National Cancer Organization, and Dr. Siegall was also honored with the recognition of Staff Fellow. This well respected recognition for his dedication powered his drive to donate to the community by publishing advanced approaches for cancer patients. Dr. Clay Siegall, in addition brought to completion his goal to institute his own institution, Seattle Genetics.